{"name":"Imugene","slug":"imugene","ticker":"IMU.AX","exchange":"ASX","domain":"imugene.com","description":"Imugene Ltd is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Imugene's unique platform technologies seeks to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.","hq":"Sydney, New South Wales, Australia","founded":0,"employees":"15","ceo":"Leslie Chong","sector":"Cancer Immunotherapy / Oncolytic Viruses","stockPrice":0.15,"stockChange":0.01,"stockChangePercent":7.14,"marketCap":"$54M","metrics":{"revenue":3944100,"revenueGrowth":-36,"grossMargin":100,"rdSpend":0,"netIncome":-58503144,"cash":14136296,"dividendYield":0,"peRatio":-1.1,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-14","type":"trial","headline":"Imugene Announces Positive Interim Results from Phase 1/2 Clinical Trial of Vaxina","summary":"Imugene reported positive interim results from a Phase 1/2 clinical trial of Vaxina, its cancer vaccine targeting HER2-positive breast cancer.","drugName":"Vaxina","sentiment":"positive"},{"date":"2022-08-25","type":"deal","headline":"Imugene Enters into Collaboration Agreement with University of Melbourne","summary":"Imugene entered into a collaboration agreement with the University of Melbourne to develop new oncolytic viruses for cancer treatment.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNMHlBODU4V2RzcnUybkFoWHo0RlViWG5vYmQwYlNOZ1gwUXh6bDl0OHJuWFFFSnhYTkRsSDBJLTdPSHpUVnVnTFljZjZPV3ZaNnFzX3EwVHBlUUtXU1R6c0ZuZXRoZlpkOHVsRlRFNFF5X1otRjdhb1dKSDlZcmdCRDMyOU9XT3BrSXZSQjROZFFTZzdGSWFKT0w0WVRJRXJKRWVpX0NQSUhoVUlKLTdSeUhXRmZKNHV6?oc=5","date":"2025-12-08","type":"pipeline","source":"The Motley Fool Australia","summary":"Why Artrya, Clinuvel, Imugene, and Pilbara Minerals shares are storming higher today - The Motley Fool Australia","headline":"Why Artrya, Clinuvel, Imugene, and Pilbara Minerals shares are storming higher today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNd0RFQ2dsVGJzTnJWekMtaFlmcUhiT1NuRVhqbzIwTTRGRFd2QW8tMUFqa2JuZnFMSlBneVdjbTZxZnhFV0t5MkQ2YjBKT0dDYk9jV3U2R0JHX3NtU0JKNjdLMk9HQW1BanBTRVMxZU52aHVCTGRKUUE4M0VvbldKWUs3dkhyQVlKSC1uS0NvbzlJLXR0ZGxGZDVvWms4Y1puZHAyWVdiLWF2aDZmWWNwUXYyREZPQQ?oc=5","date":"2025-08-04","type":"pipeline","source":"Proactive financial news","summary":"Imugene’s Leslie Chong talks Azer-cel breakthrough - Proactive financial news","headline":"Imugene’s Leslie Chong talks Azer-cel breakthrough","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNV1FrUkpRbGt5d3ptRUNXSEg1UzUzV2JtMzJlUzU1anFEOE9yREdIQTJpNG5VaFpHM1M0eHlGbmpvTlI2ZDVDd0RWTXNrLW1icVpQRlhETUZiZHVTMGxQVzQ0SnppYXFVZ0lFa0xPNUpFN1AtNDgtTlhVUHljV2JsUXVUZmJLek96UTdfRzNmc09YYnFTM09yUWRJWkR3WGt4bkR4ZHF5X0hVLUVlZVpyMVJRVVg0dF9kamdpOWdIbmlibVBwbHhHdlR1YkFlR1M3QXlraw?oc=5","date":"2025-02-19","type":"pipeline","source":"Stockhead","summary":"Biocurious: Cashed up and pursuing the ‘c’ word, Imugene is on the verge of transforming cancer immunotherapy - Stockhead","headline":"Biocurious: Cashed up and pursuing the ‘c’ word, Imugene is on the verge of transforming cancer immunotherapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQT2RzUlNRQjd2NWRSRDRRV2luakgzeVpzUHZyYk8wVG1vT0FBX2ZZRDBlSkNuTmVrMHd0VXVwYUsyM1Fvb0taV3hkRmxsTHdoLTdicTl1UUp6ZGxZM1JCS2dQZ01PR1hPcEltbjV6azFJZUtaRzF5WFpBRS1mVUZmRFh5YTVQc3pXSUZmMW9vbUhDVHAwUXpPbnJVS3d3NDdIZFJsLTZuN21CakhLYWFxNEZ1NVFhQ2FXUDNjQ19pZUJFVmhZcUE?oc=5","date":"2024-04-16","type":"pipeline","source":"Fierce Pharma","summary":"CDMO Kincell inks CAR-T supply pact with Imugene, pays $6M for its North Carolina manufacturing site and staff - Fierce Pharma","headline":"CDMO Kincell inks CAR-T supply pact with Imugene, pays $6M for its North Carolina manufacturing site and staff","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNVkJhVm1KWEJXRkdFNzAtRHJPX0NRYzEzRDF2Yi1WQ01rTnVITnRKeHZmYmttMmFYTkJ0aVN1OUIxS21mbnRrbjdaSnltLW9LUThtZVdCMHQwa0VvbFBSeDFLMFRjb0k3b21BYzZ6d1U3d3BRRVRYTVRmekxCbUYzZXM2N25HVERNalByUWZlV080X28?oc=5","date":"2023-08-16","type":"pipeline","source":"BioPharma Dive","summary":"Precision sells lymphoma drug to Imugene in retreat from cell therapy research - BioPharma Dive","headline":"Precision sells lymphoma drug to Imugene in retreat from cell therapy research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPbDlZVTkzY04zeHdDUl9mY3RaNkZLeG5ZWVR0R3c3dTVrd1VGVzYzMFhybkpmQnZtdEFQTlZWWHJCMV90dnBpeW1WSmRkODZDbjI2b0U4Wng2LUdYMHdjUU1PUFZjaE5JUjN4OFNmanhDWlRSWVV0dW1YWmFNYm15UXhoaDdLTkhXR1Z3LUFvYWQ0cUo2bkw1eEJFTF9CNUItdnZlNU1WamVHUkRVdzFOZWRwSkVzYjdyUE5Pd2c5YktfQQ?oc=5","date":"2021-11-01","type":"regulatory","source":"Stockhead","summary":"ASX Health Stocks: AFT Pharma jumps 13pc on FDA submission, Imugene up 10pc on CAR-T progress - Stockhead","headline":"ASX Health Stocks: AFT Pharma jumps 13pc on FDA submission, Imugene up 10pc on CAR-T progress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQRlF4OWUwR3pTbHA3Wkl2WnhBTDZmbVlrbGRWYk1uMmhvell4MHR0Q1V5bUFYdTVuNFVpUTA2SHY5eU9JU1pjY2huLVZiUXlEYTEwdTRrN2RBV3hGU1JtMEo4Sno2cGRTeWdqS3lwWUdDbFYyUWlvcWRMY1ZIOVR0MzliemkxOEs4cHAyRGl1RQ?oc=5","date":"2021-07-06","type":"trial","source":"pharmaphorum","summary":"Imugene HER2 vaccine hits target in stomach cancer trial - pharmaphorum","headline":"Imugene HER2 vaccine hits target in stomach cancer trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQV3g3blQzRTVIa3phOXZEeUVrMWdSRmM5QkNQUlBTMVZKbWpUbnhXOXlvckpRUEhCMVcwZEl2NE5YMmpyMGFsZGNVV3BTdER1czR0U0p5NC1UUS00OHoxcTloQjJoWHZpbjFQUjNKNlRCSEpveHJJdUZMNGc3OXNXY0tnUFdzLUpDRE9VazY0WXlPU01Wc0MzSmRZSWphUU9IUUhiVDVfVm9vVVk?oc=5","date":"2019-07-25","type":"pipeline","source":"Next Investors","summary":"IMU’s Latest Cancer Treatment Acquisition Could Have Big Pharma Knocking - Next Investors","headline":"IMU’s Latest Cancer Treatment Acquisition Could Have Big Pharma Knocking","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPZ1hnUkZEQTlQVWZMQkNHMWkyQUVOS19PeHB0cDBRWUlXV05VWEdDc1FDa2h5c0pJMWNLSmhzM2dwVTZZZ1BmUDk0c2NlcmpiaFV0cHBDUzA1a0V4LUtteHZEc3lSbmpPNzNmMDRhWklJMmF6YlNqNGxpU1pZdV91V2pDRFdNQjAyNlN0MGUxQnJ2a2NweE1sdFB4VDNnQWFrNzdDSzczZlNFcUpRNlV4TWFHUHZTanhRaHAydFlXOXFkc28?oc=5","date":"2018-07-02","type":"pipeline","source":"SMH.com.au","summary":"Cancer-fighter Imugene looking to spark interest of big pharma - SMH.com.au","headline":"Cancer-fighter Imugene looking to spark interest of big pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9vMEVvandkbEh2Z09pSlk1MW9DREdFU1k1X2pXV2ctS04tYmVzZndWQXNCV2lzVDdnanV4bTRnbzdoMFduUVFlVGdPMno4U1hoODE5YXg5d0pWOWhTSDNB?oc=5","date":"2017-06-16","type":"pipeline","source":"Yahoo Finance Australia","summary":"Imugene Limited (IMU.AX) options chain - Yahoo Finance Australia","headline":"Imugene Limited (IMU.AX) options chain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE9HRFJpTURieFYySnNKSmhQUzhyamg0WnZ1YldIcGxoc3pYZjNCek1UWmZZaXpmVkwwcUVUZERGSnBlcTQ1YnpDRGF6TVd3ZTQ5N2NpWg?oc=5","date":"2017-06-10","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Actinogen Medical Limited (ACW.AX) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Actinogen Medical Limited (ACW.AX) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTFBtd1dmSXMyd3NfMHZWOEY4ckplcW9ETlV5T0NBNjVOeG5mdmhGWFhPZW5lVnMzU3JYYXZnNGNubThuZUdiTUQzcGJueUd5ZTdjd21YUw?oc=5","date":"2017-05-14","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Imugene Limited (IMU.AX) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Imugene Limited (IMU.AX) stock price, news, quote and history","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Amgen","Bristol Myers Squibb","Merck & Co."],"therapeuticFocus":["Cancer Immunotherapy","Oncolytic Viruses"],"financials":null,"yahoo":{"currentPrice":0.15,"previousClose":0.14,"fiftyTwoWeekHigh":0.95,"fiftyTwoWeekLow":0.13,"fiftyTwoWeekRange":"0.13 - 0.952","fiftyDayAverage":0.23,"twoHundredDayAverage":0.31,"beta":2.62,"enterpriseValue":36820952,"forwardPE":-1.1,"priceToBook":1.14,"priceToSales":13.7,"enterpriseToRevenue":9.34,"enterpriseToEbitda":-0.79,"pegRatio":0,"ebitda":-46916520,"ebitdaMargin":0,"freeCashflow":-2783606,"operatingCashflow":-62889440,"totalDebt":4975725,"debtToEquity":11.9,"currentRatio":1.78,"returnOnAssets":-39.2,"returnOnEquity":-111.3,"analystRating":"","recommendationKey":"none","numberOfAnalysts":1,"targetMeanPrice":0.82,"targetHighPrice":0.82,"targetLowPrice":0.82,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":13.9,"institutionHeldPercent":5,"sharesOutstanding":360255364,"floatShares":268291097,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":-0.23,"epsForward":-0.13,"revenuePerShare":0.01,"bookValue":0.13,"officers":[{"age":69,"name":"Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD","title":"Executive Chairman"},{"age":null,"name":"Ms. Leslie  Chong","title":"CEO, MD & Executive Director"},{"age":52,"name":"Mr. Darren Michael Keamy B.Com., CPA","title":"CFO & Company Secretary"},{"age":null,"name":"Dr. John  Byon M.D., Ph.D.","title":"Chief Medical Officer"},{"age":null,"name":"Ms. Ursula  McCurry","title":"Chief Clinical Operations Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.imugene.com","phone":"61 2 9423 0881"}}